MONDAY, Sept. 19, 2022 (HealthDay News) — For high-risk patients with mild-to-moderate COVID-19 during the omicron epoch, bebtelovimab seems to be a reliable treatment option, according to a study published online Sept. 17 in the Journal of Infectious Diseases.
Raymund R. Razonable, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a retrospective cohort study involving 3,607 high-risk patients to examine the effectiveness of bebtelovimab in real-world settings. A total of 2,833 patients received bebtelovimab and 774 received nirmatrelvir-ritonavir.
The researchers found that compared with nirmatrelvir-ritonavir, bebtelovimab was used more often for treatment of COVID-19 among older patients, immunosuppressed patients, and those with multiple comorbidities. The rates of progression to severe disease by 30 days after treatment were not significantly different after bebtelovimab versus nirmatrelvir-ritonavir treatment (1.4 versus 1.2 percent). The rate of admission to the intensive care unit was comparable between the groups (0.5 and 0.3 percent for those receiving bebtelovimab and nirmatrelvir-ritonavir treatment, respectively).
People are also reading…
“This study gives us confidence that bebtelovimab is reliable for the treatment of high-risk patients during this omicron epoch characterized by increasingly new variants, and gives us another tool in the effort against COVID-19,” Razonable said in a statement.
Two authors disclosed financial ties to the pharmaceutical industry.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
